金河生物：将适时调整美国控股子公司法玛威药业金霉素预混剂产品售价

Core Viewpoint - The company, Jinhe Biological, announced a price adjustment plan for its end products in response to the recent U.S. tariffs on certain raw pharmaceutical products from China, aiming to maintain product quality and service while maximizing profitability in the U.S. market [1][2] Group 1: Company Strategy - Jinhe Biological will conduct thorough market research to timely increase the end sales prices of its products in the U.S. to offset the cost impact from the tariff hikes [1] - The company emphasizes strict quality control in production to gain customer trust and expand market share, ultimately enhancing economic benefits [1][2] Group 2: Market Position and Products - As a leading supplier of chlortetracycline premix, Jinhe Biological's services cover three main areas: animal protection, environmental protection, and agricultural product processing [2] - The company offers over 90 products, including chlortetracycline series animal protection products, corn starch, and various vaccines, with an annual comprehensive production capacity of 60,000 tons for its "Muxing" brand chlortetracycline premix [2] Group 3: Market Impact - Following the announcement of the price adjustment plan, Jinhe Biological's stock price opened with a 10% increase, reaching 5.94 yuan per share, with a total market capitalization of 4.584 billion yuan [2]